Status:

COMPLETED

A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.

Lead Sponsor:

GlaxoSmithKline

Conditions:

HIV Infection

Infection, Human Immunodeficiency Virus

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

This study is a two-part study. Part one is designed to see how different formulations of GSK364735 are absorbed in the body and To see how food affects how GSK364735 is absorbed in the body. Part two...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • The subject is healthy with no clinically significant problems identified by the physician.
  • Females of non-childbearing potential and males surgically sterile or agrees to birth control.
  • Body mass Index (BMI) of 19-29.9 (kg/m2).
  • Exclusion criteria:
  • As a result of the physical examination, lab results the Investigator considers the subject unfit for the study.
  • Blood pressure and electrocardiogram is not normal
  • A history of alcohol or illicit drug abuse.
  • Tobacco use within 3 months.
  • Positive for Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody.
  • Current use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements.
  • Has participated in a clinical trial within 30 days prior to the first dose of study medication.
  • Donated a pint of blood within a 56 day period.
  • History of allergy to study drug.

Exclusion

    Key Trial Info

    Start Date :

    October 1 2006

    Trial Type :

    INTERVENTIONAL

    End Date :

    Estimated Enrollment :

    56 Patients enrolled

    Trial Details

    Trial ID

    NCT00386347

    Start Date

    October 1 2006

    Last Update

    June 4 2012

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    GSK Investigational Site

    Evansville, Indiana, United States, 47714